Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of Bomedemstat in Myeloproliferative Neoplasms
2021-002452-37Phase 2Completed
- Sponsor
- Imago BioSciences, Inc.
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bomedemstat in myeloproliferative disorder (MPD), sponsored by Imago BioSciences, Inc. Primary endpoint: Safety and tolerability of bomedemstat. Started Sep 2021; status: completed.
02
Drugs
bomedemstat
03
Conditions
myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on 2021-002452-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002452-37.